Exelixis EXEL Net debt / EBITDA

Net debt / EBITDA at other companies

Eli LillyLLY

1.3×-0.7×

PfizerPFE

3.8×—

Opko HealthOPK

1.2×—

Jazz PharmaceuticalsJAZZ

5.6×-2.2×

IncyteINCY

-2.1×+1.4×

Gilead SciencesGILD

1.4×-0.6×

FAQ

What is Exelixis's net debt / EBITDA?

Exelixis (EXEL) reported net debt / EBITDA of -0.1× in Q2 2026.

How has Exelixis's net debt / EBITDA changed year-over-year?

Exelixis's net debt / EBITDA decreased by 647.4% year-over-year, from 0× to -0.1×.

What is the long-term trend for Exelixis's net debt / EBITDA?

Over 4 years (2020 to 2025), Exelixis's net debt / EBITDA has grown at a -39.0% compound annual growth rate (CAGR), from -2.3× to -0.3×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.